Mazyar Shadman, MD, MPH
Articles
CAR T Monitoring Strategies: Balancing Patient Safety With Quality of Life Considerations
June 23rd 2025Panelists discuss how CAR T monitoring requirements have evolved from initially conservative inpatient approaches to more flexible outpatient strategies, exploring ways to reduce the burden of mandatory 30-plus-day proximity requirements while maintaining patient safety and improving treatment accessibility.
The Expanding CAR T Landscape: FDA-Approved Therapies and Clinical Impact Across B-Cell Malignancies
June 23rd 2025Panelists discuss how CAR T cell therapy has transformed lymphoma treatment with multiple FDA-approved products showing 70% to 80% overall response rates and 50% to 60% complete response rates across different B-cell malignancies, while emphasizing the importance of comparing clinical trial data with real-world evidence to understand true efficacy and safety profiles.
Clinical Features and Risk Factors: Navigating ASCT vs CAR T Therapy Decisions in R/R LBCL
March 14th 2025Experts discuss clinical features and risk factors in navigating the decision between autologous stem cell transplant (ASCT) and chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
